RUTI Immune
Invest in Ruti Immune, developing a unique vaccine that enhances "trained innate immunity" against Covid-19 and other viruses.
Invest in Ruti Immune, developing a unique vaccine that enhances "trained innate immunity" against Covid-19 and other viruses.
RUTI Immune is a biopharmaceutical startup founded in 2020 and is based in Spain. The company is dedicated to developing a unique vaccine that enhances "trained innate immunity" against Covid-19 and other viruses. It is promoted by ARCHIVEL FARMA, the owner of the renowned RUTI vaccine, which has granted the rights for its development and commercialization to this new entity.
Unlike most vaccines in development focusing on virus antigens, Ruti ® takes a different approach by enhancing the patient’s “trained innate immunity”. This approach makes it compatible with other vaccines and better suited to adapt to possible virus mutations or new strains that may emerge. The last investment made in RUTI Immune was a €1.60M Equity Crowdfunding investment on 19 January 2021.
Investing in RUTI Immune means investing in a vaccine that has the potential to reach people all over the world. With a strong focus on biopharma, biotechnology, and pharmaceutical industries, RUTI Immune presents an innovative approach to vaccine development and has the potential to make a significant impact in the fight against Covid-19 and other viruses.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Equity Crowdfunding | €1.60M | - | 19 Jan 2021 |
No recent news or press coverage available for RUTI Immune.
We care about your data, and we'd love to use cookies make your experience better.
